

1 **PCSK9 stimulates Syk, PKC δ , and NF- κ B, leading to atherosclerosis progression independently of LDL receptor**

2 Dasom Shin^{1,2,3#}, Soungchan Kim^{1,2,3#}, Hwan Lee^{1,2,3#}, Hyun-Chae Lee^{1,2}, Jaewon Lee^{1,2}, Hyun-woo Park^{1,2,4}, Mina Fukai^{1,2,3}, EunByule Choi^{1,2,3},
3 Subin Choi^{1,2,3}, Bon-Jun Koo^{1,2,3}, Ji-Hoon Yu^{1,2,3}, Gyurae No^{1,2,3}, Sungyoon Cho^{1,2,4}, Chan Woo Kim⁵, Dohyun Han², Hyun-Duk Jang^{1,2*}, and
4 Hyo-Soo Kim^{1,3,4,6*}

5 ¹Center of CBT (Cell and BioTherapy), Seoul National University Hospital, Seoul, Republic of Korea

6 ²Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea

7 ³Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea

8 ⁴Program in Stem Cell Biology, Seoul National University College of Medicine, Seoul, Republic of Korea

9 ⁵Department of Preclinical Trial, Laboratory Animal Center, Osong Medical Innovation Foundation (KBIO), Cheongju, Chungbuk, Republic of
10 Korea

11 ⁶Cardiovascular Center & Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

12 #These authors contributed equally to this work.

13 * These authors jointly supervised this work. and are co-corresponding authors.

14 Hyo-Soo Kim, MD, PhD

15 Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, Seoul 110-744, Republic of Korea

16 Tel: +82-2-2072-2226

17 Fax: +82-2-766-8904

18 E-mail: hyosoo@snu.ac.kr


19
20 Hyun-Duk Jang, PhD

21 Department of Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, Seoul 110-744, Republic of Korea

22 Tel: +82-2-2072-0218

23 E-mail: 65765@snuh.org


24



25

26 **Supplementary Fig. 1**

27 Expression of adhesion molecules in the animal experiment showing that PCSK9 aggravated atherosclerosis in *Ldlr*^{-/-} mice (Figure 2). AdV-PCSK9
 28 at 1×10^{11} infectious units/mouse was administered via the tail vein to mice on a high-fat diet. (a) Immunoblot analysis of the liver samples from *Ldlr*
 29 ^{-/-} mice showing that the expression of adhesion molecules (integrin- α 4, integrin- β 1, VCAM-1, and ICAM-1) along with PCSK9 was significantly
 30 higher in AdV-PCSK9 (N=5) mice than in AdV-CTRL (N=3) mice. (b) Immunoblot analysis of BMDMs from *Ldlr*^{-/-} mice showed no significant changes
 31 in the expression of adhesion molecules (integrin- α 4, integrin- β 1).



33

34 **Supplementary Fig. 2**

35 Effects of siRNA against CAP1 on LPS-induced phosphorylation of p65, Akt, Erk, and p38. THP-1 cells were transfected with CAP1 siRNA or non-
 36 targeting control (CTRL siRNA) and cultured for 3 days after LPS treatment in a time-dependent manner (0, 10, 30, and 60 min). Immunoblot
 37 analysis demonstrating that CAP1-deficient cells showed LPS-mediated pro-inflammatory signaling equivalent to control cells. The representative
 38 figures of three independent experiments are shown.


PCSK9 concentration and the level of phosphorylation in CAD patients

Patients	PCSK9 (serum)	pSyk	p-PKCδ	p-p65 (S276)	p-p65 (S536)
1	394.900	1.000	1.000	1.000	1.000
2	333.500	0.696	0.585	1.016	1.049
3	414.300	1.136	0.944	0.495	0.282
4	320.000	0.336	0.562	1.049	1.062
5	466.800	1.334	0.595	0.758	0.672
6	387.400	0.847	0.773	0.469	0.731
7	328.600	0.148	0.137	0.798	0.886
8	631.900	3.604	2.401	1.067	3.567
9	302.500	0.350	1.442	1.880	0.821
10	494.300	0.365	1.429	3.199	1.071
11	426.000	4.211	2.558	3.185	3.894
12	448.000	1.083	1.932	1.946	0.734
13	373.500	0.622	1.517	3.340	1.164
14	403.000	2.779	1.093	2.636	2.956
Control					
1	202.000	1.470	0.951	0.288	0.452
2	279.800	1.163	1.194	0.243	0.441
3	230.300	0.446	1.259	0.357	0.255
4	302.600	0.994	0.814	0.523	0.486
5	435.700	1.112	0.788	0.035	0.025

39

40 **Supplementary Fig. 3**

41 Correlation of serum PCSK9 and phosphorylation of Syk, PKCδ, and NF-κB in human PBMCs of CAD patients (N=14) and healthy donors (N=5) is
 42 described in Fig. 9a. The table shows the raw data of serum PCSK9 concentration (ng/mL) and quantified immunoblots of phosphorylated Syk,
 43 PKCδ, p65(S276), and p65(S536) in human PBMCs using ImageJ software (relative ratio). The quantified immunoblot raw data were normalized
 44 with patient data and plotted in a correlation graph against PCSK9 concentration.



46

47 **Supplementary Fig. 4**

48 Immunoblot analysis demonstrating the effects of time elapsed after siRNA transfection on the degree of CAP1 or TLR4 knockdown (top). THP-1
 49 cells were transfected with CAP1 or TLR4 siRNA and harvested at different time points: 0, 24, 48, and 72 hr (N=3). The representative figures of
 50 three independent experiments are shown and quantified using ImageJ software (bottom). The differences between the groups were compared
 51 using the unpaired t-test (two-tailed). All data are presented as mean values +/- SD.